



CGM in the Real T2D World

American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026. *Diabetes Care*. 2026;49(Supplement_1):S150–S165.

Barchiesi MA, Calabrese A, Costa R, et al. Continuous glucose monitoring in type 2 diabetes: a systematic review of barriers and opportunities for care improvement. *Int J Qual Health Care*. 2025;37(3):mzaf046.

Barnard-Kelly K, Woombs C, Barnard E, et al. EP190/#338 FREEDM2 Study: Real-Time Glucose Monitoring in Adults with T2D on Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: Qualitative Interviews. *Diabetes Technol Ther*. 2026;28(3):1S-448S.

Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603.

Demir C, Nitschke MJ, Brosen JMB, et al. SO030/#840 Continuous Glucose Monitoring as Technological Awareness in Adults with Type 1 Diabetes and Impaired Awareness of Hypoglycemia. *Diabetes Technol Ther*. 2026;28(3):1S-448S.

Giorgino F, Buzzetti R, Dei Cas A, et al. OP043/#906 Effectiveness of Freestyle Libre 2 on Glycemia in Adults with Type 2 Diabetes using Basal-Only Insulin in Italy. *Diabetes Technol Ther*. 2026;28(3):1S-448S.

Hall T, Warman MK, Oser T, et al. Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring. *J Am Board Fam Med*. 2024;37(4):671-679.

Leelarathna L, Moore P, Sathyapalan T, et al. EP135/#262 Impact of Freestyle Libre 3 on Sensor-Based Outcomes in Type 2 Diabetes Treated with Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: The FREEDM2 Study. *Diabetes Technol Ther*. 2026;28(3):1S-448S.

Leelarathna L, Moore P, Sathyapalan T, et al. EP371/#342 Patient Reported Outcome Measures in the FREEDM2 Randomised Controlled Trial: Freestyle Libre 3 in T2DM on Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist. *Diabetes Technol Ther*. 2026;28(3):1S-448S.

Martens TW, Parkin CG. How use of continuous glucose monitoring can address therapeutic inertia in primary care. *Postgrad Med*. 2022;134(6):576-588.



CGM in the Real T2D World

Mateu NCI, Nielsen EM, Iken MK, et al. SO074/#464 Early Benefits of Continuous Glucose Monitoring with Age-Specific Education in Older Adults. *Diabetes Technol Ther.* 2026;28(3):1S-448S.

Miller EM. Using Continuous Glucose Monitoring in Clinical Practice. *Clin Diabetes.* 2020;38(5):429-438.

Oser TK, Hall TL, Dickinson LM, et al. Continuous Glucose Monitoring in Primary Care: Understanding and Supporting Clinicians' Use to Enhance Diabetes Care. *Ann Fam Med.* 2022;20(6):541-547.

Rodriguez JA, Prada-Rey N, Gao C, et al. Language Disparities in Continuous Glucose Monitoring for Type 2 Diabetes. *JAMA Netw Open.* 2025;8(6):e2516523.

Rowlands A, Yates T, Taylor S, et al. SO039/#133 Short-Term CGM Use with Minimal Instruction Drives Behavioral Change in Non-Insulin-Treated Type 2 Diabetes: GPS Can Identify those Most Likely to Benefit. *Diabetes Technol Ther.* 2026;28(3):1S-448S.

Simonson GD, Holt EH, Grady M, et al. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report. *Clin Diabetes.* 2024;42(4):550-560.

Toschi E, Slyne C, Savory M, et al. SO037/#396 Physical Activity Levels in the FREEDM2 Randomized Controlled Trial: Freestyle Libre 3 in Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitors and/or GLP-1 Agonist. *Diabetes Technol Ther.* 2026;28(3):1S-448S.

Wallia A, Agarwal S, Owen AL, et al. Disparities in Continuous Glucose Monitoring Among Patients Receiving Care in Federally Qualified Health Centers. *JAMA Netw Open.* 2024;7(11):e2445316.

Wilmot E, Moore P, Sathyapalan T, et al. OP046/#221 Efficacy of Freestyle Libre 3 on HbA1c in Type 2 Diabetes Treated with Basal Insulin Plus SGLT2 Inhibitor and/or GLP-1 Agonist: The FREEDM2 Study. *Diabetes Technol Ther.* 2026;28(3):1S-448S.